New York, February 10, 2026, 13:15 ET — Regular session.
- BSX rose about 0.7% to $74.61 by early afternoon after Monday’s 2.8% drop.
- New four-year Farapulse data and analyst notes kept attention on Boston Scientific’s heart-rhythm franchise.
- The next major catalyst is CHAMPION-AF trial results slated for ACC.26 on March 28.
Shares of Boston Scientific Corp rose about 0.7% to $74.61 in early afternoon trading on Tuesday, after a choppy start to the week. About 9.1 million shares had traded by 1:15 p.m. in New York.
The stock is trying to steady after last week’s earnings report knocked it off its highs and made investors question how fast the company can grow in 2026. The heat is on its electrophysiology business — catheters and other gear used to treat heart rhythm disorders.
Fresh data from the 2026 AF Symposium has pushed Farapulse back into the conversation. Pulsed field ablation, or PFA, uses electrical pulses rather than heat or cold to disable tissue that triggers atrial fibrillation.
Boston Scientific said a four-year follow-up from the observational extension of its pivotal ADVENT trial showed higher treatment success for Farapulse than thermal ablation (72.8% versus 64.1%), with no long-term safety concerns. Truist Securities analysts described Farapulse as a “workhorse” platform in a note to investors on Monday, while Citi Research analysts wrote on Sunday that PFA demand remains robust. Johnson & Johnson and Abbott also brought new atrial-fibrillation data to the meeting, keeping competitive pressure in view. MedTech Dive
Boston Scientific fell 2.82% on Monday to close at $74.12, underperforming even as the S&P 500 rose 0.47%. Trading volume hit 21.1 million shares, well above its 50-day average, and the stock ended the session about 32% below its 52-week high of $109.50, MarketWatch data showed.
On Tuesday, medical-device peers traded firmer: Abbott was up about 1.4%, Medtronic gained roughly 0.9% and Johnson & Johnson edged higher, while Stryker added nearly 2.8%. A broad-market proxy, the SPDR S&P 500 ETF, was little changed.
The bigger move came last Wednesday, when Boston Scientific sank as much as 17% after quarterly sales in electrophysiology missed Wall Street estimates. “Their worries were not misplaced,” Citi analyst Joanne Wuensch said at the time; CEO Michael Mahoney said he was “really pleased” with the segment’s 35% organic growth and told analysts he expects to outpace a market he sees growing about 15% in 2026. Reuters
That reset left the stock sensitive to anything that hints at slowing procedure growth or heavier discounting to win accounts. It does not take much: a small miss in a high-growth franchise can turn into a big multiple hit.
The next clear catalyst sits on the calendar. The American College of Cardiology’s ACC.26 program lists primary results from the CHAMPION-AF trial as a late-breaking presentation on Saturday, March 28, in New Orleans.
CHAMPION-AF compares left atrial appendage closure — a procedure that seals off a small pouch in the heart where clots can form — with NOAC blood thinners in a broad atrial-fibrillation population, Boston Scientific says. The study is designed to test whether the Watchman FLX device can support first-line use for stroke-risk reduction.
But trial readouts can disappoint, and regulators and insurers do not always move at the pace investors expect. Meanwhile, rivals are pushing their own PFA systems, and any fresh stumble in electrophysiology or Watchman demand could bring the sellers back.
For now, the stock is stuck in a tug-of-war between clinical data that supports Farapulse and numbers that have to match it. Traders will be watching for the March 28 CHAMPION-AF readout — and for any early signs, before then, that Boston Scientific’s heart-rhythm business is back on its old trajectory.
